The refill visit is where the margin actually changes.
For an Indian pharmacy chain, a chronic patient's monthly refill is the moment a branded pack can become a private-label one — roughly ₹15 of gross profit becoming roughly ₹33 on the same prescription, while the customer pays less. That conversation only happens if the patient is in front of you. OneDose makes the contact when they are not.
It is the same product the rest of this site describes. In India it is worth buying for a different reason, so we lead with that reason.
Why we don't lead with readmissions in India
Everywhere else, this company talks about post-discharge follow-up and 30-day readmissions. Here we don’t, and it is worth explaining rather than quietly swapping the pitch.
India has no readmission penalty. The word does not appear in the PM-JAY claims adjudication manual, the health benefit package manual, the NABH accreditation standards, or the IRDAI master circular. We checked all four end to end, because the claim we were about to make depended on it.
And the incentive runs backwards. PM-JAY pays a fixed package per episode, and nothing bundles a readmission into the previous one — so a readmission is admitted and paid as a new package. It earns the hospital money. PM-JAY also already includes fifteen days of post-discharge care inside the package price, which means a hospital is carrying that follow-up obligation unfunded and has every reason to spend less on it, not more.
The person a readmission actually costs is the patient’s family, through their annual floater. That is a real problem and a bad reason to expect a hospital procurement team to fund a solution.
We could dress this up. The Indian pharmacy business has a better argument anyway.
What the chronic refill visit is actually worth
Ask a pharmacy chain what chronic patients are for and you will not hear about adherence. You will hear about private label — and the arithmetic is not subtle.
On a ₹100 MRP product, a branded pack costs the retailer around ₹68 and sells around ₹83: roughly ₹15 of gross profit. The private-label equivalent costs around ₹12 and sells around ₹45: roughly ₹33. The customer saves close to half and the retailer more than doubles the margin on the same prescription. Those are MedPlus’s own numbers, given by its managing director on a filed earnings call.
And he was explicit about who converts and why: chronic patients are spending a lot of money month on month, they are coming to the store regularly, they know the store employees — and so they are the ones who actually listen. Apollo says the same thing in different words in its annual report: retention drives private-label cross-selling, a higher-margin business than pharma.
So the chronic patient is not valuable because they are sick. They are valuable because they come back, and coming back is what makes the conversation possible.
Then what is OneDose for?
The whole mechanism depends on the patient being in front of you. When the refill is due and they don’t come in, none of it happens — no conversation, no conversion, and eventually no customer.
OneDose makes that contact. When a refill is due, the agent calls or messages the patient in their language, confirms what they are still taking, and gets the refill scheduled — so the visit that your economics depend on actually occurs. Your staff still have the conversation. We just make sure there is someone to have it with.
This is the same product described everywhere else on this site. It is not a different build for India. It is a different reason to buy it, because India has a different reason.
Three reasons this might not be for you
You already discount chronic patients. Most chains do — up to 20% on larger bills, against a gross margin in the high teens. Price is the incumbent tool for chronic loyalty and it works on the people already in the store. If your chronic customers are all walking in on schedule, we have nothing to add, and you should not buy this.
You may have built it already. The online-first players run refill prompts and auto-refill in-house, because for them a missed refill is a direct loss of repeat GMV. If you have a functioning refill programme, we are a competitor to your own team, not a supplier to it — and you should take the honest version of that seriously before taking a meeting.
You want a government or insurance-funded programme. There is no line item to sell into. The national NCD budget was merged out of existence in 2022-23. PM-JAY excludes outpatient care by policy. And under the IRDAI wellness rules an insurer cannot pay a third-party vendor a programme fee at all — so if someone has told you an insurer will fund this, ask them which clause they mean.
What we comply with in India — and what we won't claim
Health data in India is sensitive personal data under the SPDI Rules 2011, and those rules are still the operative instrument today.
The DPDP Act 2023 is notified, and most of it is not yet in force. Notice, consent, security safeguards, breach reporting and data-principal rights commence in May 2027 — and so does the provision that repeals the SPDI Rules. So a vendor claiming to be “DPDP compliant” today is claiming compliance with obligations that have not started. We would rather tell you which rules actually bind us now. Neither instrument imposes a general data-localisation requirement.
On ABDM, we will not tell you we are “ABDM-ready.” That is not a term the National Health Authority uses. NHA certifies integration by milestone and publishes every certified partner, so the real claim is specific and you can check it in about thirty seconds. Ask us what our status is and we will point you at the register rather than at an adjective.
Frequently asked
- Do Indian hospitals get penalised for readmissions?
- No. There is no readmission penalty in India. The word does not appear in the PM-JAY claims adjudication manual, the health benefit package manual, the NABH hospital accreditation standards, or the IRDAI master circular on health insurance. Because PM-JAY pays a fixed package per episode, a readmission for a new condition is admitted and paid as a new package — it earns the hospital money. The cost of a readmission in India falls on the patient’s family, through their annual floater.
- So why would an Indian pharmacy chain want its chronic patients contacted?
- Because the refill visit is where private label conversion happens. Chronic patients spend monthly, come in regularly and know the store staff — which is why they are the customers who actually listen when a lower-priced private-label equivalent is suggested. On a ₹100 MRP prescription, a branded pack earns a retailer roughly ₹15 of gross profit and a private-label equivalent roughly ₹33, while the customer pays substantially less. The refill contact is the moment that conversion is possible.
- Is this a medication adherence product?
- That is the word the category uses, and it is not the word Indian pharmacy uses. Across roughly 1,550 pages of MedPlus, Apollo, PharmEasy and Wellness Forever filings, medication adherence is essentially absent as a business concept. What those companies do describe, repeatedly and in their own numbers, is chronic repeat contact and private-label mix. That is the same mechanism under a name a P&L owner already budgets for.
- We already discount chronic patients. Why would we add this?
- That is the right objection, and it is the one to test us on. Discounting is the incumbent tool for chronic loyalty and it works on the customers who are already in the store. What it does not do is reach the patient whose refill is due and who has not come in. If your chronic patients are all walking in on schedule, this product has nothing to add and we would rather say so.
- What does OneDose comply with in India?
- Today, the SPDI Rules 2011 under the IT Act, which treat health data as sensitive personal data and are still the operative instrument. The DPDP Act 2023 is notified but its substantive obligations — notice, consent, security safeguards, breach reporting and data-principal rights — commence in May 2027, and the provision repealing the SPDI Rules commences then too. Any vendor telling you they are DPDP compliant today is describing obligations that are not yet in force. There is no general data-localisation requirement under either.